New combo therapy aims to tame painful skin condition

NCT ID NCT07554014

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether combining an anti-IL-17A/F antibody (bimekizumab) with a non-ablative fractional laser can safely reduce symptoms of mild to moderate hidradenitis suppurativa, a chronic skin condition causing painful lumps. Fifty adults will receive the combination every 4 weeks for 16 weeks, with blood and skin samples taken before and after treatment. The main goal is to see if at least half of participants achieve a 50% reduction in inflammatory nodules and abscesses without worsening.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Bimekizumab (a monoclonal antibody) plus non-ablative fractional laser
What this could lead to
If it works, this combination could offer a new way to control hidradenitis suppurativa symptoms with fewer side effects than current treatments.
What could go wrong
This is a small, early-phase study with only 50 participants and no comparison group, so results may not apply broadly. Side effects from the drug or laser are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA (HS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China

    Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.